{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:07:46Z","timestamp":1773392866164,"version":"3.50.1"},"reference-count":29,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2020,3,13]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Several studies on 18F-FDG-PET\/CT have investigated the prognostic role of\nthis imaging modality in different tumors after treatment. Nevertheless, its role in restaging patients\nwith recurrent CM still needs to be defined.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The aim of this retrospective multicenter study was to evaluate the clinical and prognostic\nimpact of 18F-FDG-PET\/CT on the restaging process of cutaneous melanoma (CM) after surgery in\npatients with suspected distant recurrent disease or suspected metastatic progression disease.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p> 74 patients surgically treated for CM underwent 18F-FDG-PET\/CT for suspected\ndistant recurrent disease or suspected metastatic progression disease. The diagnostic accuracy of\nvisually interpreted 18F-FDG-PET\/CT was obtained by considering histology (n=21 patients), other\ndiagnostic imaging modalities performed within 2 months of PET\/CT (CT in 52\/74 patients and\nWhole-Body MRI in 18\/74 patients) and clinical follow-up (n=74 patients) for at least 24 months containing\nall the clinical and diagnostic information useful for the PET performance assessment and outcome.\nProgression-free survival (PFS) and overall survival (OS) were assessed by using the Kaplan-\nMeier method. The risk of progression (Hazard Ratio-HR) was computed by the Cox regression analysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Suspicion of recurrent CM was confirmed in 24\/27 patients with a positive 18F-FDG-PET\/CT\nscan. Overall, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy\nof 18F-FDG-PET\/CT were 82%, 93%, 88%, 89%, and 89%, respectively, with area under the\ncurve being 0.87 (95%IC 0.78-0.97; p&lt;0.05). 18F-FDG-PET\/CT findings significantly influenced the\ntherapeutic management in 18 patients (modifying therapy in 10 patients; guiding surgery in 8 patients).\nAfter 2 years of follow-up, PFS was significantly longer in patients with a negative vs. a positive\n18F-FDG-PET\/CT scan (90% vs 46%, p&lt;0.05; Fig. 1). Moreover, a negative scan was associated\nwith a significantly longer OS than a positive one (76% vs 39% after 2 years, p&lt;0.05; Fig. 2). In addition,\na positive 18F-FDG-PET\/CT scan was associated with an increased risk of disease progression\n(HR=8.2; p0,05).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>18F-FDG-PET\/CT showed a valuable diagnostic performance in patients with suspicion of\nrecurrent CM. This imaging modality might have an important prognostic value in predicting the survival\noutcomes, assessing the risk of disease progression, and guiding treatment decision making.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1874471012666191009161826","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T13:05:12Z","timestamp":1570626312000},"page":"42-47","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical and Prognostic Value of 18F-FDG-PET\/CT in the Restaging Process of Recurrent Cutaneous Melanoma"],"prefix":"10.2174","volume":"13","author":[{"given":"Domenico","family":"Albano","sequence":"first","affiliation":[{"name":"Unit of Diagnostic and Interventional Radiology, IRCCS Istituto Ortopedico Galeazzi, Via Riccardo Galeazzi 4, 20161 Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demetrio","family":"Familiari","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department A.R.N.A.S GARIBALDI - Nesima, Via Palermo 636, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Fornito","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department A.R.N.A.S GARIBALDI - Nesima, Via Palermo 636, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Scalisi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Fondazione Istituto G.Giglio, Ct.da Pietra Pollastra-pisciotto, Cefalu, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Laudicella","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina ME, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Galia","sequence":"additional","affiliation":[{"name":"Section of Radiological Sciences, Di.Bi.Med., University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Grassedonio","sequence":"additional","affiliation":[{"name":"Section of Radiological Sciences, Di.Bi.Med., University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department A.R.N.A.S GARIBALDI - Nesima, Via Palermo 636, Catania, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Ganduscio","sequence":"additional","affiliation":[{"name":"University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Messina","sequence":"additional","affiliation":[{"name":"Unit of Oncology, Fondazione Istituto G.Giglio, Ct.da Pietra Pollastra-pisciotto, Cefal\u00f9, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Spada","sequence":"additional","affiliation":[{"name":"Unit of Oncology, Fondazione Istituto G.Giglio, Ct.da Pietra Pollastra-pisciotto, Cefalu, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Midiri","sequence":"additional","affiliation":[{"name":"Section of Radiological Sciences, Di.Bi.Med., University of Palermo, Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierpaolo","family":"Alongi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Fondazione Istituto G.Giglio, Ct.da Pietra Pollastra-pisciotto, Cefalu, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bjd.12492","volume":"170","author":"Nikolaou V.","year":"2014","unstructured":"Nikolaou V.; Stratigos A.J.; Emerging trends in the epidemiology of melanoma. Br J Dermatol 2014,170(1),11-19","journal-title":"Br J Dermatol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"Siegel R.L.","year":"2016","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2016. CA Cancer J Clin 2016,66(1),7-30","journal-title":"CA Cancer J Clin"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/(SICI)1096-9098(199804)67:4<228:AID-JSO4>3.0.CO;2-A","volume":"67","author":"Soong S.J.","year":"1998","unstructured":"Soong S.J.; Harrison R.A.; McCarthy W.H.; Urist M.M.; Balch C.M.; Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998,67(4),228-233","journal-title":"J Surg Oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/CMR.0000000000000332","volume":"27","author":"Tas F.","year":"2017","unstructured":"Tas F.; Erturk K.; Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors. Melanoma Res 2017,27(2),134-139","journal-title":"Melanoma Res"},{"key":"ref=5","first-page":"18","volume":"6","author":"Trotter S.C.","year":"2013","unstructured":"Trotter S.C.; Sroa N.; Winkelmann R.R.; Olencki T.; Bechtel M.; A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol 2013,6(9),18-26","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00330-017-5071-x","volume":"28","author":"Galia M.","year":"2018","unstructured":"Galia M.; Albano D.; Tarella C.; Patti C.; Sconfienza L.M.; Mul\u00e8 A.; Alongi P.; Midiri M.; Lagalla R.; Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now. Eur Radiol 2018,28(3),1187-1193","journal-title":"Eur Radiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s13139-018-0537-6","volume":"52","author":"Lee H.H.","year":"2018","unstructured":"Lee H.H.; Paeng J.C.; Cheon G.J.; Lee D.S.; Chung J.K.; Kang K.W.; Recurrence of Melanoma After Initial Treatment: Diagnostic Performance of FDG PET in Posttreatment Surveillance. Nucl Med Mol Imaging 2018,52(5),327-333","journal-title":"Nucl Med Mol Imaging"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjsurg.2013.04.012","volume":"207","author":"Baker J.J.","year":"2014","unstructured":"Baker J.J.; Meyers M.O.; Frank J.; Amos K.D.; Stitzenberg K.B.; Ollila D.W.; Routine restaging PET\/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. Am J Surg 2014,207(4),549-554","journal-title":"Am J Surg"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s00259-016-3500-8","volume":"44","author":"Alongi P.","year":"2017","unstructured":"Alongi P.; Caobelli F.; Gentile R.; Stefano A.; Russo G.; Albano D.; Baldari S.; Gilardi M.C.; Midiri M.; Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET\/CT. Eur J Nucl Med Mol Imaging 2017,44(2),224-233","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/MNM.0000000000000862","volume":"39","author":"Albano D.","year":"2018","unstructured":"Albano D.; Familiari D.; Gentile R.; Scalisi S.; Midiri F.; Messina M.; Spada M.; Fornito M.C.; Galia M.; Midiri M.; Alongi P.; Clinical and prognostic value of 18F-FDG-PET\/CT in restaging of pancreatic cancer. Nucl Med Commun 2018,39(8),741-746","journal-title":"Nucl Med Commun"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00259-017-3797-y","volume":"44","author":"Eiber M.","year":"2017","unstructured":"Eiber M.; Rauscher I.; Souvatzoglou M.; Maurer T.; Schwaiger M.; Holzapfel K.; Beer A.J.; Prospective head-to-head comparison of C-choline-PET\/MR and C-choline-PET\/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2017,44(13),2179-2188","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00259-017-3811-4","volume":"45","author":"Alongi P.","year":"2018","unstructured":"Alongi P.; Evangelista L.; Caobelli F.; Spallino M.; Gianolli L.; Midiri M.; Picchio M.; Diagnostic and prognostic value of 18F-FDG PET\/CT in recurrent germinal tumor carcinoma. Eur J Nucl Med Mol Imaging 2018,45(1),85-94","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-018-0278-7","volume":"\u2022","author":"Fiasconaro E.","year":"2018","unstructured":"Fiasconaro E.; Caobelli F.; Quartuccio N.; PET\/CT for the diagnostic assessment of patients with renal cancer. Clin Transl Imaging, 2018,\u2022","journal-title":"Clin Transl Imaging,"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1007\/s40336-018-0277-8","volume":"\u2022","author":"Albano D.","year":"2018","unstructured":"Albano D.; Caobelli F.; Quartuccio N.; PET\/CT for the diagnostic assessment of patients with testicular cancer. Clin Transl Imaging, 2018,\u2022","journal-title":"Clin Transl Imaging,"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"Boellaard R.","year":"2010","unstructured":"Boellaard R.; O\u2019Doherty M.J.; Weber W.A.; Mottaghy F.M.; Lonsdale M.N.; Stroobants S.G.; Oyen W.J.; Kotzerke J.; Hoekstra O.S.; Pruim J.; Marsden P.K.; Tatsch K.; Hoekstra C.J.; Visser E.P.; Arends B.; Verzijlbergen F.J.; Zijlstra J.M.; Comans E.F.; Lammertsma A.A.; Paans A.M.; Willemsen A.T.; Beyer T.; Bockisch A.; Schaefer-Prokop C.; Delbeke D.; Baum R.P.; Chiti A.; Krause B.J.; FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010,37(1),181-200","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/SLA.0b013e318256d1f5","volume":"256","author":"Beasley G.M.","year":"2012","unstructured":"Beasley G.M.; Parsons C.; Broadwater G.; Selim M.A.; Marzban S.; Abernethy A.P.; Salama A.K.; Eikman E.A.; Wong T.; Zager J.S.; Tyler D.S.; A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET\/CT in patients with AJCC stage IIIB or IIIC extremity melanoma. Ann Surg 2012,256(2),350-356","journal-title":"Ann Surg"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.1097\/RLU.0000000000001275","volume":"41","author":"Mena E.","year":"2016","unstructured":"Mena E.; Taghipour M.; Sheikhbahaei S.; Mirpour S.; Xiao J.; Subramaniam R.M.; \n                        F-FDG PET\/CT and melanoma: value of fourth and subsequent posttherapy follow-up scans for patient management. Clin Nucl Med 2016,41(9),e403-e409","journal-title":"Clin Nucl Med"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/annonc\/mdy124","volume":"1;29","author":"Lewin J","year":"2018","unstructured":"Lewin J; Sayers L; Kee D; Walpole I; Sanelli A; Marvelde, LT Surveillance imaging with FDG-PET\/CT in the post-operative follow-up of stage 3 melanoma. Ann Oncol, 2018,1;29(7),1569-1574","journal-title":"Ann Oncol,"},{"key":"ref=19","first-page":"255","volume":"7","author":"Vensby P.H.","year":"2017","unstructured":"Vensby P.H.; Schmidt G.; Kj\u00e6r A.; Fischer B.M.; The value of FDG PET\/CT for follow-up of patients with melanoma: a retrospective analysis. Am J Nucl Med Mol Imaging 2017,7(6),255-262","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"MMT06","DOI":"10.2217\/mmt-2017-0022","volume":"5","author":"Perissinotti A.","year":"2018","unstructured":"Perissinotti A.; Rietbergen DD.; Vidal-Sicart S.; Riera AA.; Olmos, RAV Melanoma","journal-title":"Melanoma Manag"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2967\/jnumed.116.183111","volume":"58","author":"Taghipour M.","year":"2017","unstructured":"Taghipour M.; Marcus C.; Sheikhbahaei S.; Mena E.; Prasad S.; Jha A.K.; Solnes L.; Subramaniam R.M.; Clinical indications and impact on management: fourth and subsequent posttherapy follow-up 18F-FDG PET\/CT scans in oncology patients. J Nucl Med 2017,58(5),737-743","journal-title":"J Nucl Med"},{"key":"ref=22","first-page":"1323","volume":"45","author":"Fuster D.","year":"2004","unstructured":"Fuster D.; Chiang S.; Johnson G.; Schuchter L.M.; Zhuang H.; Alavi A.; Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004,45(8),1323-1327","journal-title":"J Nucl Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1245\/s10434-010-0963-x","volume":"17","author":"Aukema T.S.","year":"2010","unstructured":"Aukema T.S.; Olmos R.A.V.; Korse C.M.; Kroon B.B.; Wouters M.W.; Vogel W.V.; Bonfrer J.M.; Nieweg O.E.; Utility of FDG PET\/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. Ann Surg Oncol 2010,17(6),1657-1661","journal-title":"Ann Surg Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3413\/Nukmed-0584-13-05","volume":"52","author":"Wieder H.A.","year":"2013","unstructured":"Wieder H.A.; Tekin G.; Rosenbaum-Krumme S.; Klode J.; Altenbernd J.; Bockisch A.; Nagarajah J.; 18FDG-PET to assess recurrence and long term survival in patients with malignant melanoma. Nucl Med (Stuttg) 2013,52(5),198-203","journal-title":"Nucl Med (Stuttg)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.03.5634","volume":"24","author":"Reinhardt M.J.","year":"2006","unstructured":"Reinhardt M.J.; Joe A.Y.; Jaeger U.; Huber A.; Matthies A.; Bucerius J.; Roedel R.; Strunk H.; Bieber T.; Biersack H.J.; T\u00fcting T.; Diagnostic performance of whole body dual modality 18F-FDG PET\/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006,24(7),1178-1187","journal-title":"J Clin Oncol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/jdv.12078","volume":"28","author":"Jouvet J.C.","year":"2014","unstructured":"Jouvet J.C.; Thomas L.; Thomson V.; Yanes M.; Journe C.; Morelec I.; Bracoud L.; Durupt F.; Giammarile F.; Berthezene Y.; Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study. J Eur Acad Dermatol Venereol 2014,28(2),176-185","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ejrad.2009.04.059","volume":"75","author":"Laurent V.","year":"2010","unstructured":"Laurent V.; Trausch G.; Bruot O.; Olivier P.; Felblinger J.; R\u00e9gent D.; Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT. Eur J Radiol 2010,75(3),376-383","journal-title":"Eur J Radiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/jmri.25439","volume":"45","author":"Albano D.","year":"2017","unstructured":"Albano D.; Patti C.; Lagalla R.; Midiri M.; Galia M.; Whole-body MRI, FDG-PET\/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. J Magn Reson Imaging 2017,45(4),1082-1089","journal-title":"J Magn Reson Imaging"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejrad.2018.04.014","volume":"103","author":"Albano D.","year":"2018","unstructured":"Albano D.; Patti C.; Matranga D.; Lagalla R.; Midiri M.; Galia M.; Whole-body diffusion-weighted MR and FDG-PET\/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD. Eur J Radiol 2018,103,90-98","journal-title":"Eur J Radiol"}],"container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/175508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T08:24:19Z","timestamp":1585383859000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/175508\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,13]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471012666191009161826","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-15","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}